February 2012

Vivus rockets 99% on FDA nod

Vivus rockets 99% on FDA nod

Marketwatch

Satori snags $15M to fuel a trial on Alzheimer's drug

Satori snags $15M to fuel a trial on Alzheimer's drug

Fierce Biotech

Novartis Urged To Drop Gleevec Patent Case

Novartis Urged To Drop Gleevec Patent Case

Pharmalot

Par Pharma Absorbs Edict Pharma

Par Pharma Absorbs Edict Pharma

Yahoo/Zacks

Medicines Co 4Q profit slides, trumps expectations

Medicines Co 4Q profit slides, trumps expectations

Yahoo/AP

Paladin and Somaxon Announce Filing of New Drug Submission for Silenor

Paladin and Somaxon Announce Filing of New Drug Submission for Silenor

Yahoo

MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile

MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile

Yahoo

Johnson & Johnson CEO is Out, but not Gone

Johnson & Johnson CEO is Out, but not Gone

TheStreet.com

Ranbaxy Reports $606 Million Loss After U.S. Settlement

Ranbaxy Reports $606 Million Loss After U.S. Settlement

Bloomberg

FDA panel overwhelmingly backs previously rejected anti-obesity pill Qnexa

FDA panel overwhelmingly backs previously rejected anti-obesity pill Qnexa

Washington Post, DC